Wed May 21 11:10:00 UTC 2025: **Summary:**
HSBC downgraded UnitedHealth Group (UNH) stock to “Sell” and significantly lowered its price target due to mounting concerns about the company’s future. This follows a week of setbacks for UNH, including a CEO change, withdrawn financial outlook, and a stock price plummet. Key concerns cited by the analyst include a higher-than-expected medical loss ratio, legislative uncertainty regarding pharmacy benefit managers (PBMs) and drug pricing, and the potential for a delayed recovery into 2026-27 due to Medicaid funding cuts. While some see the stock’s current discount as a buying opportunity, the analyst believes the risks are not fully priced in and the valuation should be lower, especially given increased earnings uncertainty.
**News Article:**
**UnitedHealth Stock Plummets as HSBC Issues “Sell” Rating Amid Growing Concerns**
**New York, NY** – UnitedHealth Group (UNH) shares are facing renewed pressure after HSBC downgraded the stock to “Sell” from “Hold” and slashed its price target to $270, a significant drop from the previous $490. The move reflects growing analyst unease surrounding the healthcare giant’s prospects following a tumultuous week.
The downgrade, issued by HSBC analyst Sidharth Sahoo, comes on the heels of a CEO shakeup, the withdrawal of the company’s financial outlook, and a five-year low for the stock. Several other analysts have also reduced their price targets in recent days.
Sahoo pointed to a number of key concerns that are weighing on UNH’s valuation. These include a higher-than-anticipated medical loss ratio (MLR) for 2025, projected at 88.1% compared to the company’s prior guidance of 87-88%, raising fears of sustained high healthcare costs. The analyst also cited significant legislative uncertainty regarding pharmacy benefit managers (PBMs) and the potential implementation of a most-favored nation (MFN) drug pricing model, which could negatively impact revenue streams for Optum, UnitedHealth’s pharmacy services arm.
Furthermore, Sahoo expects a delayed recovery for UnitedHealth, potentially extending into 2026-27, due in part to Medicaid funding cuts impacting Medicare Advantage profitability. He believes that the change in CEO presents an opportunity for “kitchen sinking,” a strategy where the new leadership absorbs all potential financial hits upfront to reset expectations.
“Earnings uncertainty has increased after UnitedHealth withdrew its 2025 guidance,” Sahoo wrote in a note to investors. “We believe this will give the new CEO an opportunity for ‘kitchen sinking’.”
While some investors view UnitedHealth’s current 30% discount to its historical price-to-earnings (P/E) ratio as an attractive entry point, Sahoo argues that the aforementioned risks are not yet fully priced into the stock.
Despite the recent downgrade, Wall Street consensus on UNH remains a “Strong Buy,” based on 19 Buy ratings and 7 Hold ratings issued in the last three months. However, the average price target of $390 implies a 21.28% upside potential, significantly higher than HSBC’s revised target.
The downgrade from HSBC is likely to further rattle investors who have already witnessed significant volatility in UNH stock in recent weeks. The coming months will be critical as the company navigates legislative challenges, manages its MLR, and works to restore investor confidence under its new leadership.
First Piper 